Navigation Links
Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
Date:6/24/2010

Quincy Bioscience, a research-based biotechnology company, announced interim results from the Prevagen Memory Study. The Prevagen Memory Study is a three-month long, randomized, double-blind, placebo controlled study using both qualitative Quality of Life surveys and a quantitative, computer-based set of cognitive tests developed by Cogstate Ltd.

Madison, WI (Vocus) June 24, 2010 -- Quincy Bioscience, a research-based biotechnology company, announced interim results from the Prevagen Memory Study. The Prevagen Memory Study is a three-month long, randomized, double-blind, placebo controlled study using both qualitative Quality of Life surveys and a quantitative, computer-based set of cognitive tests developed by Cogstate Ltd.

Prevagen showed statistically significant improvement over placebo at Day 60 in measures of spatial working memory and executive function in thirty five generally healthy adults reporting memory concerns prior to the start of the trial. The Prevagen arm showed a 14% reduction in the number of total errors compared to Day 0. The average age of this initial cohort was 61 years old and sixty eight percent of the participants were female. A statistically significant improvement was also seen in the change from baseline (Day 0) measurements. “We are encouraged by what this preliminary look at the data from this study has shown us,” said KC Lerner, Manager of Business Development.

Prevagen contains the calcium-binding protein apoaequorin. Apoaequorin has demonstrated neuroprotection in pre-clinical studies performed at the University of Wisconsin-Milwaukee. Apoaequorin was originally isolated from Aequorea victoria, a species of jellyfish found in the Puget Sound.

“The relationship between intracellular calcium imbalance and age-related cognitive decline is well-established. The data shows that Prevagen is a new tool for staying cognitively fit as we age. With 78 million baby boomers getting older every day, helping people with memory concerns is our first priority,” said Quincy Bioscience President Mark Underwood. Quincy Bioscience is also looking at several health conditions that are believed to be the result of disruptions in calcium homeostasis and intends to study the effect of Prevagen in these conditions.

About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

###

Read the full story at http://www.prweb.com/releases/quincybioscience/memorydata/prweb4188374.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
2. Quincy Bioscience Sponsors Multiple Sclerosis (MS) Scholarship Program
3. Euthymics Bioscience Collaborates with GlobalSign and SafeNet to Provide an FDA Approved Electronic Signature Solution
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
5. Thriving Bioscience Region Leaves Its Mark
6. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
7. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
8. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
9. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
10. Exalenz Bioscience Expands Market Coverage for the BreathID Breath Test System
11. Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential"
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
(Date:4/28/2017)... VA (PRWEB) , ... April 28, 2017 , ... The ... volunteer board members and officers for 2017-2018. The annual board election process has been ... on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, ...
(Date:4/28/2017)... ... 28, 2017 , ... From April 30 to May 3, ... will host industry leaders for the annual spring Convention & Expo, called Momentum ... adapt to the issues currently affecting urgent care and on-demand healthcare. , “Momentum ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... responds to and which He does not. Yisrayl says with so many titles and ... true name, but he says with a little Scripture, backed with a lot of research, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, ... through its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging ... the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract ...
(Date:4/28/2017)... MEMPHIS, Tenn. (PRWEB) , ... April 28, 2017 , ... ... VeinViewer® system, today announced an alliance with B. Braun Medical Inc. , a ... central role in patient care with as many as 90 percent of hospital patients ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology: